Mürşide Genç
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mürşide Genç has a total of 200 co-authors. Here are the top co-authors by number of shared publications:
- Abdullah Yildirim
Department of Cardiology, University of Health Sciences, Adana City Training and Research Hospital, 01230 Adana, Türkiye
2 shared publications - Eda Macit Aydın
Department of Critical Care Medicine, Ankara Etlik City Hospital, Ankara, Türkiye
2 shared publications - Fahri Er
Department of Cardiology, Bandırma Training and Research Hospital, Bandırma Onyedi Eylül University, Balıkesir 10200, Türkiye
2 shared publications - Gökhan Kılınç
Department of Anesthesiology and Reanimation, University of Health Sciences, Balıkesir Atatürk City Hospital, 10100 Balıkesir, Türkiye
2 shared publications - Hakan Dayanır
University of Health Sciences Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
2 shared publications - Hamza Gültekin
Dicle University
2 shared publications
Latest Publications
- 14 October 2024
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 55 (1) , e14332
Modification, validation and comparison of Naples prognostic score to determine in‐hospital mortality in ST‐segment elevation myocardial infarction
Aim: The relationship between inflammatory status and poor outcomes in acute coronary syndromes is a significant area of current research. This study investigates the association between in‐hospital mortality and the modified Naples prognostic score (mNPS) as well as other inflammatory biomarkers in STEMI patients.Methods: This single‐centre, cross‐sectional study included 2576 consecutive STEMI patients who underwent primary percutaneous coronary intervention between January 2022 and November 2023. Participants were randomly divided into derivation and validation cohorts in a 6:4 ratio. The following inflammatory indices were calculated: pan‐immune‐inflammation value (PIV), systemic immune‐inflammation‐index (SII), systemic inflammation‐response index (SIRI) and conventional NPS. The mNPS was derived by integrating hs‐CRP into the conventional NPS. The performance of these indices in determining in‐hospital mortality was assessed using regression, calibration, discrimination, reclassification and decision curve analyses.Results: Inflammatory biomarkers, including PIV, SII, SIRI, NPS and mNPS, were significantly higher in patients who died during in‐hospital follow‐up compared to those discharged alive in both the derivation and validation cohorts. Multivariable logistic regression analyses were performed separately for the derivation and validation cohorts. In the derivation cohort, mNPS was associated with in‐hospital mortality (aOR = 1.490, p < .001). Similarly, in the validation cohort, mNPS was associated with in‐hospital mortality (aOR = 2.023, p < .001). mNPS demonstrated better discriminative and reclassification power than other inflammatory markers (p < .05 for all). Additionally, regression models incorporating mNPS were well‐calibrated and showed net clinical benefit in both cohorts.Conclusion: mNPS may be a stronger predictor of in‐hospital mortality in STEMI patients compared to the conventional scheme and other inflammatory indices.
- 14 October 2024
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 55 (1) , e14332
Modification, validation and comparison of Naples prognostic score to determine in‐hospital mortality in ST‐segment elevation myocardial infarction
Aim: The relationship between inflammatory status and poor outcomes in acute coronary syndromes is a significant area of current research. This study investigates the association between in‐hospital mortality and the modified Naples prognostic score (mNPS) as well as other inflammatory biomarkers in STEMI patients.Methods: This single‐centre, cross‐sectional study included 2576 consecutive STEMI patients who underwent primary percutaneous coronary intervention between January 2022 and November 2023. Participants were randomly divided into derivation and validation cohorts in a 6:4 ratio. The following inflammatory indices were calculated: pan‐immune‐inflammation value (PIV), systemic immune‐inflammation‐index (SII), systemic inflammation‐response index (SIRI) and conventional NPS. The mNPS was derived by integrating hs‐CRP into the conventional NPS. The performance of these indices in determining in‐hospital mortality was assessed using regression, calibration, discrimination, reclassification and decision curve analyses.Results: Inflammatory biomarkers, including PIV, SII, SIRI, NPS and mNPS, were significantly higher in patients who died during in‐hospital follow‐up compared to those discharged alive in both the derivation and validation cohorts. Multivariable logistic regression analyses were performed separately for the derivation and validation cohorts. In the derivation cohort, mNPS was associated with in‐hospital mortality (aOR = 1.490, p < .001). Similarly, in the validation cohort, mNPS was associated with in‐hospital mortality (aOR = 2.023, p < .001). mNPS demonstrated better discriminative and reclassification power than other inflammatory markers (p < .05 for all). Additionally, regression models incorporating mNPS were well‐calibrated and showed net clinical benefit in both cohorts.Conclusion: mNPS may be a stronger predictor of in‐hospital mortality in STEMI patients compared to the conventional scheme and other inflammatory indices.
- Open Access
- 22 November 2023
- Published by Galenos Yayinevi in Thoracic Research and Practice
- Vol. 25 (1) , 11-16
Evaluation of Patients with COVID-19 Followed Up in Intensive Care Units in the Second Year of the Pandemic: A Multicenter Point Prevalence Study
COVID-19,intensive care,intensive care unit,pandemic,follow-up
- 22 November 2023
- Published by Galenos Yayinevi in Thoracic Research and Practice
- Vol. 25 (1) , 11-16
Open AccessEvaluation of Patients with COVID-19 Followed Up in Intensive Care Units in the Second Year of the Pandemic: A Multicenter Point Prevalence Study
COVID-19,intensive care,intensive care unit,pandemic,follow-up
- Open Access
- 20 October 2023
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 40 (6) , 435-444
The Impact of CoronaVac Vaccination on 28-day Mortality Rate of Critically Ill Patients with COVID-19 in Türkiye
Background: Vaccines against coronavirus disease-19 (COVID-19) have been effective in preventing symptomatic diseases, hospitalizations, and intensive care unit (ICU) admissions. However, data regarding the effectiveness of COVID-19 vaccines in reducing mortality among critically ill patients with COVID-19 remains unclear.Aims: To determine the vaccination status and investigate the impact of the COVID-19 vaccine on the 28-day mortality in critically ill patients with COVID-19.Study Design: Multicenter prospective observational clinical study.Methods: This study was conducted in 60 hospitals with ICUs managing critically ill patients with COVID-19. Patients aged >= 18 years with confirmed COVID-19 who were admitted to the ICU were included. The present study had two phases. The first phase was designed as a one-day point prevalence study, and demographic and clinical findings were evaluated. In the second phase, the 28-day mortality was evaluated.Results: As of August 11, 2021, 921 patients were enrolled in the study. The mean age of the patients was 65.42 +/- 16.74 years, and 48.6% (n = 448) were female. Among the critically ill patients with COVID-19, 52.6% (n = 484) were unvaccinated, 7.7% (n = 71) were incompletely vaccinated, and 39.8% (n = 366) were fully vaccinated. A subgroup analysis of 817 patients who were unvaccinated (n = 484) or who had received two doses of the CoronaVac vaccine (n = 333) was performed. The 28-day mortality rate was 56.8% (n = 275) and 57.4% (n = 191) in the unvaccinated and two-dose CoronaVac groups, respectively. The 28-day mortality was associated with age, hypertension, the number of comorbidities, type of respiratory support, and APACHE II and sequential organ failure assessment scores (p < 0.05). The odds ratio for the 28-day mortality among those who had received two doses of CoronaVac was 0.591 (95% confidence interval: 0.413-0.848) (p = 0.004).Conclusion: Vaccination with at least two doses of CoronaVac within six months significantly decreased mortality in vaccinated patients than in unvaccinated patients.
- 20 October 2023
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 40 (6) , 435-444
Open AccessThe Impact of CoronaVac Vaccination on 28-day Mortality Rate of Critically Ill Patients with COVID-19 in Türkiye
Background: Vaccines against coronavirus disease-19 (COVID-19) have been effective in preventing symptomatic diseases, hospitalizations, and intensive care unit (ICU) admissions. However, data regarding the effectiveness of COVID-19 vaccines in reducing mortality among critically ill patients with COVID-19 remains unclear.Aims: To determine the vaccination status and investigate the impact of the COVID-19 vaccine on the 28-day mortality in critically ill patients with COVID-19.Study Design: Multicenter prospective observational clinical study.Methods: This study was conducted in 60 hospitals with ICUs managing critically ill patients with COVID-19. Patients aged >= 18 years with confirmed COVID-19 who were admitted to the ICU were included. The present study had two phases. The first phase was designed as a one-day point prevalence study, and demographic and clinical findings were evaluated. In the second phase, the 28-day mortality was evaluated.Results: As of August 11, 2021, 921 patients were enrolled in the study. The mean age of the patients was 65.42 +/- 16.74 years, and 48.6% (n = 448) were female. Among the critically ill patients with COVID-19, 52.6% (n = 484) were unvaccinated, 7.7% (n = 71) were incompletely vaccinated, and 39.8% (n = 366) were fully vaccinated. A subgroup analysis of 817 patients who were unvaccinated (n = 484) or who had received two doses of the CoronaVac vaccine (n = 333) was performed. The 28-day mortality rate was 56.8% (n = 275) and 57.4% (n = 191) in the unvaccinated and two-dose CoronaVac groups, respectively. The 28-day mortality was associated with age, hypertension, the number of comorbidities, type of respiratory support, and APACHE II and sequential organ failure assessment scores (p < 0.05). The odds ratio for the 28-day mortality among those who had received two doses of CoronaVac was 0.591 (95% confidence interval: 0.413-0.848) (p = 0.004).Conclusion: Vaccination with at least two doses of CoronaVac within six months significantly decreased mortality in vaccinated patients than in unvaccinated patients.
- 1 January 2023
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 17 (2) , 59-72
Comparison of Thromboembolic Risk Scores for Evaluating In-Hospital Events of Covid-19 Patients
Aim: To compare the effectiveness of thromboembolic risk scores in determining in-hospital events of COVID-19 patients. Methods: This retrospective study included a total of 410 consecutive COVID-1... Plain language summary COVID-19 continues to be a pandemic that threatens human health all over the world. The main aim of our study was to examine the relationship between risk scores routinely us... Tweetable abstract Thromboembolism has been of paramount importance in further understanding the pathophysiology of COVID-19. Learn more about the association of various thromboembolism risk scores...
- 1 January 2023
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 17 (2) , 59-72
Comparison of Thromboembolic Risk Scores for Evaluating In-Hospital Events of Covid-19 Patients
Aim: To compare the effectiveness of thromboembolic risk scores in determining in-hospital events of COVID-19 patients. Methods: This retrospective study included a total of 410 consecutive COVID-1... Plain language summary COVID-19 continues to be a pandemic that threatens human health all over the world. The main aim of our study was to examine the relationship between risk scores routinely us... Tweetable abstract Thromboembolism has been of paramount importance in further understanding the pathophysiology of COVID-19. Learn more about the association of various thromboembolism risk scores...